BioSpecifics, Endo, Swedish Orphan Biovitrum sales and marketing update

NICE issued final draft guidance recommending against Xiapex collagenase clostridium histolyticum from Swedish Orphan to treat Dupuytren’s contracture in adult patients with a palpable cord. The agency said it recommends the injectable form of collagenase for research-use only.

This guidance is in line with NICE’s draft guidance issued in February, which was withdrawn to allow the company to submit more information. In its latest guidance, the agency said more research is needed comparing the drug to existing treatments for the indication before it can determine if it is a clinically and cost-effective option for routine use (see BioCentury, March 23). ...